News >

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC

Jason Harris
Published: Monday, Dec 11, 2017

Sandra Horning, MD

Sandra Horning, MD
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1–positive advanced or metastatic renal cell carcinoma (mRCC).

Two (2%) patients in the sunitinib arm and 1 (1%) patient assigned to the combination died due to an AE.
Powles T, McDermotee SF, Rini B, et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). In: Proceedings from the 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract LBA39.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication